Is ketamine going to be Psychedelic Therapy’s opening act? At medium to large doses, Ketamine evokes colorful visions and mystical type experiences that have been linked to positive treatment outcomes. And—unlike other psychedelics—Ketamine has been readily available at clinics worldwide for 50 years.
Psilocybin and MDMA have gotten much attention for their potential efficacy in treating some of the most prevalent psychiatric conditions of our time, such as depression, trauma and anxiety disorders. Phase-3-studies are well underway, effect sizes look promising and therapists around the globe are being trained to bring this new and potentially groundbreaking treatment to the masses. However, clinical approval of psilocybin and MDMA might still be a long way ahead of us. In the meantime, some within the psychedelic community are looking to see whether ketamine may be able to fill the gap.
Read more…